NIPT PrenaTest



PrenaTest is the first Non Invasive Prenatal Diagnostic (NIPD) developed by LifeCodexx in Germany for the detection of fetal trisomy 21(Down’s syndrome), 18(Edwards Syndrome) and 13(Patau Syndrome). The test analyzes circulating cell free fetal DNA (ccffDNA) in the maternal blood and is a new option in the prenatal testing paradigm for detecting fetal aneuploidies.

PrenaTest is the only CE-marked non-invasive molecular genetics blood test. It has successfully completed the conformity assessment procedures required for CE marking, thus proven its efficiency in terms of the in-vitro diagnostics (IVD) directive of the European Union.

When is it sensible to carry out the PrenaTest?

It is indicated for high risk pregnancies if you fall under a risk group of any of the aforementioned trisomies based on advanced age, abnormal ultrasound findings or a pregnancy history of aneuploidy.

Kindly consult with your Obstetrician about how high your personal risk is that your baby might carry a trisomy 21, 18 and 13

How is the PrenaTest carried out?

After you have undergone genetic counseling by your physician and signed a declaration of consent, 20 ml blood will be drawn from you for analysis. This blood sample is sent to LifeCodexx certified laboratories in Germany on the same day. The results will be available to your Physician within 15 days, who will then inform you about the outcome.

PrenaTest is commercially available in Middle East and North Africa (MENA) region.

For further information related to the test and its availability in clinics in your country of residence, please contact us at:

Phone: +971 4  4227010
Email: prenatest@genpharmservices.com
 

For more information about the collaboration between Genpharm and LifeCodexx, please visit our news section.